Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Completed · Phase 4

Conditions studied: Rheumatoid Arthritis (RA)

In brief

This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.

Key facts

Study ID

NCT02541955

Run by

Veena Ranganath, MD, MS

People needed

40

Starts

2017-07-20

Expected to finish

2025-05-20

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must meet 1987 ACR criteria
• Age > 18 years of age
• Baseline DAS28/Erythrocyte Sedimentation Rate (ESR) >=3.2
• Stable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)
• Stable prednisone <10mg or equivalent
• Power Doppler score of >=10

You may not qualify if…

• Prior treatment with Acthar in the past 2mos
• Meet one of the above RA flare requirements
• Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

Where it is running

• UCLA David Geffen School of Medicine, Division of Rheumatology — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.